Occult connective tissue diseases mimicking idiopathic interstitial pneumonias

European Respiratory Journal

Volumn 31, Issue 1, 2008, Pages 11-20

  Tzelepis, G E ^a,b   Toya, S P ^a,b   Moutsopoulos, H M ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Connective tissue related; Idiopathic pulmonary fibrosis; Interstitial lung diseases

Indexed keywords

RIBONUCLEOPROTEIN; AUTOANTIBODY;

ANTISYNTHETASE SYNDROME; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; HUMAN; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUPUS VULGARIS; MUSCULOSKELETAL SYSTEM; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOLOGICAL MODEL; BIOPSY; CHEMISTRY; CLINICAL CHEMISTRY; DIFFERENTIAL DIAGNOSIS; INTERSTITIAL LUNG DISEASE; LUNG; LUNG FIBROSIS; METHODOLOGY; PATHOLOGY; PHYSICAL EXAMINATION; PNEUMONIA; PULMONOLOGY;

AUTOANTIBODIES; BIOPSY; CHEMISTRY, CLINICAL; CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; PHYSICAL EXAMINATION; PNEUMONIA; PULMONARY DISEASE (SPECIALTY); PULMONARY FIBROSIS;

EID: 45849099854     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00060107     Document Type: Review

References (108)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Raghu G, Brown KK. Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clin Chest Med 2004; 25: 409-419: v.
3. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203.
4. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.
5. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142: 963-967.
6. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
7. Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998; 113: 192-202.
8. Flaherty KR, Andrei AC, King TE Jr, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007; 175: 1054-1060.
9. Crestani B. The respiratory system in connective tissue disorders. Allergy 2005; 60: 715-734.
10. Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119: 471-503.
11. Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med 1989; 10: 677-722.
12. Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002; 22: S151-S165.
13. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J 2001; 18: Suppl. 32, 69s-80s.
14. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 10-17.
15. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25: 549-559: vii.
16. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44: 585-596.
17. Fujita J, Ohtsuki Y, Yoshinouchi T, et al. Idiopathic non-specific interstitial pneumonia: as an "autoimmune interstitial pneumonia". Respir Med 2005; 99: 234-240.
18. Homma Y, Ohtsuka Y, Tanimura K, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration 1995; 62: 248-251.
19. Felicio CH, Parra ER, Capelozzi VL. Idiopathic and collagen vascular disease nonspecific interstitial pneumonia: clinical significance of remodeling process. Lung 2007; 185: 39-46.
20. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis- dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182-1185.
21. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167: 1410-1415.
22. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
23. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
24. Schwarz MI, Albert RK. "Imitators" of the ARDS: implications for diagnosis and treatment. Chest 2004; 125: 1530-1535.
25. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-Th/To-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006; 33: 1600-1605.
26. Highland KB, Heffner JE. Pleural effusion in interstitial lung disease. Curr Opin Pulm Med 2004; 10: 390-396.
27. Cottin V, Donsbeck AV, Revel D, et al. Nonspecific interstitial pneumonia. Individualization of a clinico-pathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158: 1286-1293.
28. Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003; 22: 245-250.
29. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
30. Nakamura Y, Chida K, Suda T, et al. Nonspecific interstitial pneumonia in collagen vascular diseases: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 235-241.
31. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
32. Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130: 976-981.
33. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 2000; 6: 424-429.
34. Eisenberg H, Dubois EL, Sherwin RP, Balchum OJ. Diffuse interstitial lung disease in systemic lupus erythematosus. Ann Intern Med 1973; 79: 37-45.
35. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982.
36. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003; 123: 1096-1103.
37. Imbert-Masseau A, Hamidou M, Agard C, et al. Antisynthetase syndrome. Joint Bone Spine 2003; 70: 161-168.
38. Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614-622.
39. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17: 701-706.
40. Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005; 44: 1282-1286.
41. Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005; 32: 58-64.
42. Clawson K, Oddis CV. Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995; 38: 1519-1523.
43. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 2006; 28: 1005-1012.
44. Sato T, Fujita J, Yamadori I, et al. Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders. Rheumatol Int 2006; 26: 551-555.
45. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003; 32: 273-284.
46. el-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol 2002; 46: 560-565.
47. Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54: 597-613.
48. Krain L. Dermatomyositis in six patients without initial muscle involvement. Arch Dermatol 1975; 111: 241-245.
49. Miyazaki E, Ando M, Muramatsu T, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 2007; 26: 436-439.
50. Sakamoto N, Mukae H, Fujii T, et al. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 2004; 43: 838-842.
51. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77: 1019-1038.
52. Ohosone Y, Ishida M, Takahashi Y, et al. Spectrum and clinical significance of autoantibodies against transfer RNA. Arthritis Rheum 1998; 41: 1625-1631.
53. Sauty A, Rochat T, Schoch OD, et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997; 10: 2907-2912.
54. Bernstein RM, Morgan SH, Chapman J, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. BMJ (Clin Res Ed) 1984; 289: 151-152.
55. Chmiel JF, Wessel HU, Targoff IN, Pachman LM. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol 1995; 22: 762-765.
56. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 360-374.
57. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26: 459-467.
58. Nash P, Schrieber L, Webb J. Interstitial lung disease as the presentation of anti-Jo-1 positive polymyositis. Clin Rheumatol 1987; 6: 282-286.
59. Plastiras SC, Soliotis FC, Vlachoyiannopoulos P, Tzelepis GE. Interstitial lung disease in a patient with antisynthetase syndrome and no myositis. Clin Rheumatol 2007; 26: 108-111.
60. Steen VD. Systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 641-654.
61. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-440.
62. Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
63. Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 759-767.
64. Ferri C, Bernini L, Gremignai G, et al. Lung involvement in systemic sclerosis sine scleroderma treated by plasma exchange. Int J Artif Organs 1992; 15: 426-431.
65. Lomeo RM, Cornella RJ, Schabel SI, Silver RM. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87: 525-527.
66. Slobodin G, Rosner I, Rozenbaum M, et al. Systemic sclerosis sine scleroderma: is it always the same disease? Report of three patients and discussion. Rheumatol Int 2002; 22: 170-172.
67. Vano SD, Arranz GG, Yglesias PJ. Systemic sclerosis sine scleroderma presenting as pulmonary intersticial fibrosis. Clin Rheumatol 2006; 25: 382-383.
68. Rodnan GP, Fennell RH Jr. Progressive systemic sclerosis sine scleroderma. JAMA 1962; 180: 665-670.
69. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43: 444-451.
70. Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48: 203-209.
71. Reddy R, Tan EM, Henning D, et al. Detection of a nucleolar 7-2 ribonucleoprotein and a cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983; 258: 1383-1386.
72. Okano Y, Medsger TA Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990; 33: 1822-1828.
73. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-281.
74. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16: 513-537.
75. Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: 242-254.
76. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622-627.
77. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156: 528-535.
78. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998;19, 667-685: viii.
79. Kim DS. Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006; 12: 346-353.
80. Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis? Eur Respir J 1994; 7: 817-820.
81. Roschmann RA, Rothenberg RJ. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum 1987; 16: 174-185.
82. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-2027.
83. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-386.
84. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-715.
85. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren's syndrome: why autoimmune epithelitis? Oral Dis 2006; 12: 523-532.
86. Moutsopoulos HM, Chused TM, Mann DL, et al. Sjögren's syndrome (sicca syndrome): current issues. Ann Intern Med 1980; 92: 212-226.
87. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. Chest 1985; 88: 226-229.
88. Papiris SA, Maniati M, Constantopoulos SH, et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999; 58: 61-64.
89. Deheinzelin D, Capelozzi VL, Kairalla RA, et al. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996; 154: 794-799.
90. Strimlan CV, Rosenow EC III, Divertie MB, Harrison EG Jr. Pulmonary manifestations of Sjögren's syndrome. Chest 1976; 70: 354-361.
91. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest 2006; 130: 1489-1495.
92. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171: 632-638.
93. Bodolay E, Szekanecz Z, Devenyi K, et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 2005; 44: 656-661.
94. Maddison PJ. Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 111-124.
95. Prakash UB. Respiratory complications in mixed connective tissue disease. Clin Chest Med 1998;19, 733-746: ix.
96. Saito Y, Terada M, Takada T, et al. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 2002; 26: 349-357.
97. Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Amsterdam, Excerpta Media, 1987; pp. 33-40.
98. Alarcon GS. Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 125-137.
99. Mosca M, Tani C, Neri C, et al. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006; 6: 1-4.
100. Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol 2002; 29: 2345-2349.
101. Chapman JR, Charles PJ, Venables PJ, et al. Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1984; 130: 439-443.
102. Kinder BW, Collard HR, Koth L, et al. Idiopathic non-specific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691-697.
103. Locke GR III. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 1996; 25: 1-19.
104. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456.
105. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142.
106. Kidd K, Cusi K, Mueller R, et al. Detection and identification of significant ANAs in previously determined ANA negative samples. Clin Lab 2005; 51: 517-521.
107. Pourmand N, Blomberg S, Ronnblom L, et al. Ro 52kD autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol 2000; 29: 116-123.
108. Damoiseaux JG, Tervaert JW. From ANA to ENA: how to proceed? Autoimmun Rev 2006; 5: 10-17.